Followers | 72 |
Posts | 4235 |
Boards Moderated | 2 |
Alias Born | 08/21/2015 |
Thursday, March 23, 2023 10:43:58 PM
Mentioned: CMPS DMTTF MNMD
This is the third article of a three-part series, you can find the first and second stories here.
Ketamine-assisted therapy has been in the headlines lately as several clinics have closed down and others reaffirmed they are continuing to be providers of these services.
One example is NYC-based Nushama, whose co-founder Jay Godfrey replied to a couple of industry inquiries in a recent interview with Benzinga.
Accessibility
How did ketamine become so broadly prescribed and administered? Godfrey suggests that 'the overhang and the halo effect' of ketamine therapy's efficacy under medical supervision is partly responsible for its inclusion in the COVID extension of the Ryan Haigh Act waiver, though oversight and regulation are necessary, as well as thoughtfulness in terms of who administers these medications, how, and to whom and where.
Most patients come to Nushama directly, though a small portion are referred by psychiatrists, psychologists, primary care physicians or addictions specialists.
The clinic's ketamine therapy main protocol is $4,500 though discounts and alternative payment plans are available for veterans and first responders. An 8-member group therapy discount, which cuts the price in half, and scholarships are also available.
'About 15% of patients get what we call the â??hero's journey' discount (veterans and first responders, including nurses, doctors and school teachers). Since we have offered it, the demographics of our members base have changed drastically,' Godfrey told Benzinga.
Godfrey confirmed that classic insurance companies are not yet including psychedelic therapy, though the clinic is in discussions with third-party administrators like Enthea.
Competition And Business Growth
Godfrey noted that the NYC population is so vast and the need for these kinds of therapies is so great that not even filling every Nushama room every single hour of every day would cover the current demand.
While the brand is planning to expand its clinic services most likely to Philadelphia, Washington DC, Boston, Toronto and Florida, they're facing two general constraints.
'One, fundraising markets are not what they were, let's call it, in 2020 and 2021, so we are being cautious; but also and more importantly, psychedelics companies should see these medicines as sacred tools. So before spreading the Earth with Nushama locations, we want to make sure we are doing this right in every location, and part of that is finding the right doctor in every city and the right set of nurses and medical assistance, as well as location,' Godfrey says.
Also, the co-founder positions Nushama as 'molecule agnostic,' meaning once other psychedelics are approved for use in the mental health treatment space, they will administer 'so long as we feel we can do it safely and according to the standards that we feel are necessary.'
Godfrey believes all these other molecules will never be self-administered at home, and that the drug development community, including COMPASS (NASDAQ: CMPS), MindMed (NASDAQ: MNMD), atai (NASDAQ: ATAI) and Small Pharma OTCMKTS: DMTTF), recognizes that they are going to require, even before legalization, sites that are responsible to conduct clinical research.
Requirements would include clinics with experience in psychedelic administration that can act as delivery channels for these medicines.
That's why, Godfrey confirms that conversations have begun between Nushama and these psychedelics-developing companies, adding that it is still too early to determine what psilocybin or MDMA legalization would look like in clinical practice.
Recent MNMD News
- MindMed to Participate in June Conferences • Business Wire • 05/28/2024 11:00:00 AM
- MindMed to Participate at May Investor Conferences • Business Wire • 05/09/2024 08:01:00 PM
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US • Business Wire • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:15:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:12 PM
- MindMed Reports First Quarter 2024 Financial Results and Business Updates • Business Wire • 05/08/2024 08:01:00 PM
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York • Business Wire • 05/04/2024 12:00:00 PM
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update • Business Wire • 05/02/2024 11:00:00 AM
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:56:37 PM
- MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 • Business Wire • 03/01/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:45:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:20:33 PM
FEATURED DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM